Vertex Pharmaceuticals Incorporated (VRTX) Stock
NASDAQVRTX has an Alpha Score of 62 out of 100 (moderate), computed on Nov 2, 2026 from 3 of 4 sub-scores. 16 members of Congress disclosed 28 trades in VRTX since 2015: 13 purchases and 15 sales, most recently David J. Taylor (sale, Aug 26, 2026). 7 of the hedge funds AlphaScala tracks reported VRTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $270.17M. Its trailing P/E ratio is 29.2 and its net margin 35.0% (key statistics as of Oct 22, 2026).
What is VRTX's Alpha Score?
How it works →Alpha Score of 62 reflects moderate overall profile with strong momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Vertex Pharmaceuticals Incorporated (VRTX)?
Most recent: David J. Taylor (sale, Aug 26, 2026); records start May 13, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dave Taylor R-OH · House | 2026-08-26 | sale | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Dave Taylor R-OH · House | 2026-01-29 | sale | $1k – $15k |
| Dave Taylor R-OH · House | 2025-08-07 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-11 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-10 | partial sale | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $15k – $50k |
| Byron Donalds R-FL · House | 2025-03-20 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded VRTX, with filing lags →Which hedge funds own VRTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 544K | $270.17M | +72% |
| Citadel Ken Griffin | 510K | $253.55M | +50% |
| Millennium Management Israel Englander | 468K | $232.67M | +1420% |
| Renaissance Technologies Jim Simons (founder) | 320K | $158.96M | -24% |
| Bridgewater Associates Ray Dalio | 11K | $5.40M | -19% |
| D.E. Shaw David Shaw | 3K | $1.54M | -99% |
| Point72 Steve Cohen | 3K | $1.30M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Vertex Pharmaceuticals Incorporated insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Apr 1, 26 | Liu Joy | EVP and Chief Legal Officer | SELL | 978 | $439K |
| Mar 27, 26 | Bozic Carmen | EVP and CMO | SELL | 2.3K | $1.1M |
| Mar 13, 26 | Bozic Carmen | EVP and CMO | SELL | 2.3K | $1.1M |
| Mar 11, 26 | Mckechnie Duncan | EVP, Chief Commercial Officer | SELL | 2.6K | $1.3M |
| Mar 4, 26 | Mckechnie Duncan | EVP, Chief Commercial Officer | SELL | 2.4K | $1.2M |
| Mar 2, 26 | Liu Joy | EVP and Chief Legal Officer | SELL | 892 | $442K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 400 | $192K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 120 | $58K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 240 | $116K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 2.5K | $1.2M |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are VRTX's key statistics?
Key statistics as of Oct 22, 2026
How does VRTX's valuation compare with the Healthcare sector?
| Metric | VRTX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 29.2 | 27.2 | 99 |
| Net margin | 35.00% | 4.85% | 143 |
| Return on equity | 23.31% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
VRTX price chart
Powered by TradingViewWhat does Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals Incorporated is a leading biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It specializes in the discovery, development, and commercialization of transformative therapies, with a primary focus on cystic fibrosis (CF), a life-threatening genetic disease. The company markets a portfolio of CF treatments, including TRIKAFTA/KAFTRIO for patients aged 2 and older with at least one F508del mutation, ALYFTREK for those 6 years and older, SYMDEKO/SYMKEVI and ORKAMBI for patients 6 years and 1 year or older respectively, and KALYDECO for infants as young as 1 month with specific CF mutations. Vertex Pharmaceuticals Incorporated plays a pivotal role in the pharmaceuticals and biotech sector by addressing unmet needs in rare diseases through innovative small-molecule drugs. Its pipeline extends beyond CF into areas like acute and neuropathic pain, with candidates such as VX-548 advancing toward regulatory approval. With trailing twelve-month revenue of approximately $9.72 billion and a market capitalization around $86-101 billion, the company demonstrates significant financial strength and global market presence across multiple exchanges.